(2026). Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study. Neurology and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study."
Neurology and Therapy 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study."
Neurology and Therapy, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.